Cardiol Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cardiol Therapeutics generated cash of -$25,180, which is more than the previous year. Cash used in financing activities reached the amount of -$55,376 last year. Net change in cash is therefore -$24,538,089.
Cash Flow
| 2017 | -1.29M | -29.17K | 3.67M |
|---|---|---|---|
| 2018 | -10.89M | -13.79K | 25.28M |
| 2019 | -11.38M | -424.30K | 2.02M |
| 2020 | -9.18M | -40.60K | 16.29M |
| 2021 | -23.55M | -12.91K | 93.43M |
| 2022 | -27.22M | -74.70K | -53.93K |
| 2023 | -25.18K | -64.31K | -55.37K |
CRDL.TO Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 59.46K | 83.89M | 14.02M | 6.95M | 16.73M | 2.35M | 0 |
Operating activities | |||||||
Net income | -28.12M | -30.93M | -31.63M | -20.64M | -13.68M | -15.89M | -1.66M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 248.35K | 219.90K | 220.42K | 229.53K | 150.57K | 91.49K | 53.34K |
Stock-based compensation expense | 4.17M | 5.01M | 8.49M | 2.76M | 3.26M | 0 | 237 |
| Deferred income tax benefit | 4.17M | 5.01M | 8.49M | 2.76M | 3.26M | 0 | 237 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 67.17K | -144.18K | -59.94K | 707.94K | -467.08K | 0 | -101.74K |
Inventories | 0 | -4.47M | 17.96K | 1.10M | 142.57K | 0 | 0 |
Accounts payable | 0 | 4.47M | 2.39M | -707.94K | 467.08K | 1.96M | 176.71K |
Cash generated by operating activities | -25.18K | -27.22M | -23.55M | -9.18M | -11.38M | -10.89M | -1.29M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -64 | -74.70K | -12.91K | -40.60K | -424.30K | -13.79K | -29.17K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -64.31K | -74.70K | -12.91K | -40.60K | -424.30K | -13.79K | -29.17K |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 84.08M | 17.25M | 1.66M | 14.23M | 3.39M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -53.93K | -51.91K | -50.47K | 0 | 0 | 400K |
Cash used in financing activities | -55.37K | -53.93K | 93.43M | 16.29M | 2.02M | 25.28M | 3.67M |
Net Change In Cash | -24.53M | -24.42M | 69.87M | 7.06M | -9.77M | 14.37M | 2.35M |
Cash at end of period | 34.93K | 59.46M | 83.89M | 14.02M | 6.95M | 16.73M | 2.35M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |